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Abstract | The discovery of bacteria in the female urinary bladder has fundamentally changed current 13 
dogma regarding the urinary tract and related urinary disorders. Previous research characterized many 14 
of the bacterial components of the female urinary tract, but the viral fraction of this community is 15 
largely unknown. Viruses within the human microbiota far outnumber bacterial cells, with the most 16 
abundant viruses being those that infect bacteria (bacteriophages). Similar to observations within the 17 
microbiota of the gut and oral cavity, preliminary surveys of the urinary tract and bladder microbiota 18 
indicate a rich diversity of uncharacterized bacteriophage (phage) species. Phages are vital members of 19 
the microbiota, having critical roles in shaping bacterial metabolism and community structure. Despite 20 
the fact that phages have been discovered in the urinary tract, such as phages that infect Escherichia 21 
coli, sampling them is challenging owing to low biomass, possible contamination when using noninvasive 22 
methods, and the invasiveness of methods that reduce the potential for contamination. Phages could 23 
influence bladder health, but an understanding of the association between phage communities, 24 
bacterial populations, and bladder health is in its infancy. However, evidence suggests that phages can 25 
defend the host against pathogenic bacteria and, therefore, modulation of the microbiome using phages 26 
has therapeutic potential for lower urinary tract symptoms. Furthermore, as natural predators of 27 
bacteria, phages have garnered renewed interest for their use as antimicrobial agents, for instance in 28 
the treatment of urinary tract infections. 29 
 30 
• Phages are abundant members of the microbiota of the lower urinary tract. 31 
• Active or lytic phages have been isolated from urine samples, but the majority of phages within 32 
the urinary microbiota persist through dormant infections, the lysogenic life cycle. 33 
• Evidence suggests that phages have a role in modulating the composition of the urinary 34 
microbiota, similar to that observed in microbiota of other organs of the human body. 35 
• Phage therapy, or the use of phages to treat pathogenic bacterial infections, is an active area of 36 
research within urology, given their potential use to treat urinary tract infections. 37 
 38 




Bacteriophages (phages) are ubiquitous viruses that infect bacteria; they are the most abundant 41 
biological entities, far exceeding even bacteria 1. Surveys of the marine environment have resulted in an 42 
estimated prevalence of 1030 phages in the oceans alone, meaning that for each bacterial cell in the 43 
ocean there are ~10 phages 1. In addition to their abundance within the marine environment 2, phages 44 
are prevalent within the soil 3,4 and in freshwater 5. Phages have even been isolated from some of the 45 
most inhospitable conditions, including desert sands 6, sea ice 7, and the depths of the ocean 8. In 46 
addition to our surroundings, phages are abundant in and on plants 9 and within the bodies of insects 47 
and mammals 10,11. Indeed, the human gut alone is home to an estimated 2 trillion phages 12, greatly 48 
exceeding the number of eukaryotic viruses in our bodies 13. Although phages are unable to infect 49 
eukaryotic cells, evidence has been reported of direct interactions, such as direct transcytosis of phages 50 
across cell layers of the gut, lung, liver, kidney and brain 15, between phages and human cells 14,15. 51 
However, the full extent of direct and indirect effects of phages is unknown, as researchers have only 52 
just begun to speculate about the roles of phages in the human body, including the human immune and 53 
central nervous systems 12. 54 
As phage genomes can be dsDNA, ssDNA, double-stranded RNA (dsRNA), or ssRNA, linear or circular, 55 
and even segmented, sequencing phage populations often is limited by the genomic nucleic acid 56 
extraction protocol and might need amplification before sequencing 16. Amplification can introduce 57 
biases such as quantitative biases, the preferential amplification of ssDNA viruses, stochastic biases, 58 
systemic biases 17-19. Nevertheless, whole-genome sequencing technologies have enabled researchers to 59 
identify new phage species. In contrast to cellular organisms, no universal marker exists for phages 60 
because no gene is conserved within all phages. To identify phages, researchers often target genes that 61 
encode structural proteins such as phylogenetic markers 20. However, these signature sequences are far 62 
from comprehensive 21. Only a small fraction of phage sequence diversity is represented in extant 63 
sequence databases, and it is heavily biased for sequences of phages with DNA genomes that infect 64 
bacterial species that are routinely studied in the laboratory, such as E. coli, Pseudomonas spp., and 65 
Bacillus spp. 22-24. Metagenomics, the high-throughput sequencing of mixed, complex communities of 66 
microbes, has enabled exploration of the diversity of phages on Earth 2-5 and the human body 25-31, 67 
including in the lower urinary tract 32-36. 68 
The Human Microbiome Project (HMP), which characterized human microbiota using 16S ribosomal RNA 69 
sequencing and metagenomic whole-genome shotgun sequencing, revolutionized our understanding of 70 
bacteria that inhabit the human body 37. However, the bladder was not included in the HMP 71 
publications, which focused on the oral cavity, nasal cavity, skin, gastrointestinal tract, and vagina 37,38. In 72 
the absence of a urinary tract infection (UTI), the bladder was thought to be sterile and so it was not 73 
included in the HMP 39. This dogma resulted, in part, from the widespread use of standard clinical 74 
microbiology urine culture protocols, which are designed to detect common fast-growing pathogens 75 
with basic nutrient needs and no aversion to oxygen (especially E. coli). Thus, the standard protocol does 76 
not detect anaerobes, slow-growing bacteria, or bacteria with complex needs. However, diverse 77 
bacterial and fungal species have been detected in urine obtained directly from the bladder via 78 
transurethral catheterization (herein catheterization) or suprapubic aspiration that is negative using 79 
standard culture using an enhanced urine culture method called expanded quantitative urine culture 80 
(EQUC) and/or DNA sequencing methods, such as Lactobacillus, Corynebacterium, Streptococcus, 81 
Actinomyces, Staphylococcus, Aerococcus, Gardnerella, Saccharomyces and Candida spp. 40-49. These and 82 
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other studies of the bladder microbiome and microbiota have revealed associations of bladder bacteria 83 
with postoperative UTIs 50,51, urgency urinary incontinence (UUI) 44,45,47, and response to overactive 84 
bladder treatment 52. For instance, the microbiome of women with UUI had increased levels of 85 
Gardnerella spp. and decreased Lactobacillus spp. relative to the microbiome of women without UUI 44. 86 
Some bacteria are even associated with the lack of symptoms and an abundance of L. iners seems to 87 
provide protection against post-instrumentation UTI 46,50,51,53,54. These results suggest that the bladder 88 
might possess its own protective microbiota and that dysbiosis results in disorders, such as UTI and UUI 89 
55,56. An effort to generate a genomic catalogue of bacteria isolated from the bladder that was published 90 
in 2018 revealed that the genomes of bladder bacteria are quite distinct from bacteria isolated from the 91 
gut, but somewhat similar to those of the vagina 57. This suggests an interlinked female urogenital 92 
microbiota, i.e. strains resident of the vaginal community could be transferred to the urinary tract and 93 
vice versa. 94 
Although the HMP focused on characterizing the bacterial fraction of the human microbiota, sequencing 95 
of some viral genomes was unavoidable because viral DNA was present in the samples and because 96 
prophage DNA (a stage in the lysogenic cycle of temperate phages when the phage genome is either 97 
integrated into the host genome or remains in the cytoplasm as a self-replicating plasmid) was present 98 
within the bacteria 58. Subsequent to the original initiative, bacterial and viral communities within the 99 
five niches studied in the HMP were extensively investigated 59, most notably the communities 100 
inhabiting the gastrointestinal tract as it is a high biomass niche and can be studied using stool samples 101 
as a proxy. These viral communities include both eukaryotic viruses and phages. The gut virome (the 102 
viral component of the microbiome) has been the focus of numerous studies 25-31, each leading to the 103 
same conclusion: phages are key members of the gut microbiota. A core phage community exists within 104 
the gut of healthy individuals 30and disruption of this core phage community (dysbiosis) has been 105 
associated with certain gastrointestinal symptoms and disease, such as Crohn’s disease and ulcerative 106 
colitis 27,29-31,60,61. Within the gut, seven phage taxa were found to be associated with type 2 diabetes, 107 
establishing a type 2 diabetes-specific gut phage community 62. Other studies have characterized the 108 
viromes of the body sites included in the HMP 63-68; the data from these studies are publicly available 109 
(Table 1). Like the gut, associations between phage communities and patient symptoms and/or disease 110 
have been identified in these other body sites. For example, phages within the oral cavity have been 111 
linked to periodontitis 65. In contrast to the sites of the HMP, investigation of the phage communities 112 
within other niches of the human body has only recently begun. These associations within the gut and 113 
oral cavity are active areas of investigation as the extent to which phages modulate the human 114 
microbiota remains an open question. Furthermore, phage communities and their putative role in 115 
disease and/or symptoms have yet to be determined in the other niches studied within the HMP. 116 
Although the investigation of the urinary microbiota was launched independent and subsequent to the 117 
HMP, considerable progress has been made in characterizing this niche. Investigations into the phages 118 
of the lower urinary tract present challenges unique to this niche, but have greatly benefited from the 119 
work of their predecessors exploring the viromes of the five HMP niches. 120 
Studies of the bacterial communities of both the lower urinary tract in women and men have revealed a 121 
diverse community of species. Furthermore, studies of the urinary microbiome have documented 122 
clinical relevance of bladder bacteria; including associations with urinary symptom levels, treatment 123 
response, and UTI risk 42,44,45,51-54,69-72. Phages are the most abundant biological entities in the human 124 
body, and given observations made in other organs phages are probably vital members of the lower 125 
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urinary tract microbiota with the potential contribution to urinary symptoms and/or disease. Their role 126 
in the lower urinary tract is largely unknown. In this Review, we describe the current knowledge of 127 
phages within the urinary tract and their possible contribution to urinary tract health. We provide a brief 128 
introduction to phages followed by a discussion of both culture-based and culture-independent studies 129 
of the viruses of the urinary tract. We present some of the challenges in studying the urinary microbiota. 130 
Finally, we consider the clinical relevance and applications of phages. Both historical and current 131 
applications of phage therapy for lower urinary tract infections and other disorders are discussed. 132 
 133 
[H1] The phage life cycle 134 
Phages have three distinct, generally well-characterized life cycles for propagation and reproduction: 135 
lytic, lysogenic and chronic 72. All phages infect their bacterial host by binding to surface receptors, a 136 
process called adsorption (Fig. 1); these receptor binding proteins are often quite specific, leading to a 137 
narrow range of hosts (strains or species) that a particular phage can infect 73. Following adsorption into 138 
the host cell, the phage injects its DNA or RNA genome into the host’s cytoplasm. In the lytic cycle, the 139 
phage genome replicates and phage proteins are synthesized 74. For double-stranded DNA (dsDNA) 140 
phages, DNA is inserted into the protein procapsid, whereas for single-stranded DNA (ssDNA) and single-141 
stranded RNA (ssRNA) phages, the capsid is formed around the nucleic acid (Fig. 1). The bacterium’s cell 142 
wall breaks (’bursts’); phage proteins called holins can form holes in the cytoplasmic membrane or 143 
spanins can degrade the outer membrane 74, and the phage progeny disperse into the surrounding 144 
environment. Some phages are obligately lytic, but others, called temperate phages, can alternate 145 
between the lysogenic and lytic cycles. In the lysogenic cycle, the phage genome is either integrated into 146 
the host genome or remains in the cytoplasm as a self-replicating plasmid 75 (Fig. 1). The phage genome 147 
(now called a prophage) generally replicates in synchrony with the host chromosome, some phage 148 
genes are also known expressed by the bacterium. 75. Temperate phages, such as the model phage λ, are 149 
capable of going through the lytic and lysogenic cycles. Their prophages can remain dormant for 150 
generations until, often, an environmental cue, such as host starvation, change in nutrients, 151 
temperature 75,76, triggers entry into the lytic cycle — a process known as induction. This switch between 152 
the lysogenic and lytic cycle can also be determined by the phage-produced peptide communication 153 
system (the ‘arbitrium’ system), in which progeny phage lysogenize when this peptide is abundant 154 
within the environment 77. In addition to the lytic and lysogenic cycles, phages can reproduce by chronic 155 
infection; in this process phages, for example the filamentous phage M13, are shed from the bacterial 156 
cell without killing the host cell 78. The majority of known phages can be associated with one of these 157 
three life cycles, but additional modes of infection and reproduction, such as pseudolysogeny, have 158 
been described 72,76,78. 159 
Given these multiple mechanisms of infection and persistence, unsurprisingly phages can have profound 160 
effects on microbial communities (Fig. 1). Phages can transform a microbial community through 161 
predation (lysis) 79-81. Furthermore, phages can affect bacterial diversity within a community 82-85, 162 
including adaptation in susceptible host species such as loci associated with phage resistance 86,87. 163 
Coevolving lytic phages can increase diversity within bacterial populations by selecting for multiple 164 
modes of resistance 84. Phages have also been shown to alter apparent competition among bacterial 165 
strains 84. Exposure to temperate phages can increase bacterial virulence (a process referred to as 166 
lysogenic conversion) 88,89 by, for example, encoding toxins 90,91. Case reports detail shiga toxin-167 
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producing Escherichia coli strains, most commonly associated with enteric infections, found within the 168 
urine of individuals with UTIs 92-94. In this example, the shiga toxin is carried by a phage, integrated 169 
within the E. coli genome. Thus, lysogeny can be beneficial for the bacterial host 95. Some temperate 170 
phages can transfer genetic material from one cell to another (the process of transduction (Fig 2)) 171 
because they integrate their genome into their host’s genome; this process can benefit the recipient 172 
host cell. Indeed, temperate phages are well known to mediate horizontal gene transfer (HGT) and have 173 
helped spread virulence and/or resistance factors through bacterial communities 96. Similarly, lytic 174 
phages can also transfer bacterial DNA via transduction 97. Data exist that support both frequent and 175 
infrequent phage-mediated spread of antibiotic resistance genes 98-101. Phages also can contribute to 176 
HGT indirectly; for example a 2017 study identified two ‘superspreader’ phages, which are phages that 177 
promote extensive plasmid transformation 102. In this scenario, phage lysis spreads intact host plasmids, 178 
enabling HGT via transformation. The two superspreader phages discovered were 50-times more 179 
efficient in dispersing antibiotic resistance genes 102. Given the large genetic diversity present within 180 
phage communities 103, investigation of the complexities of phage-host dynamics is in very early stages 181 
22,31,104,105. 182 
 183 
[H1] Viruses of the urinary tract 184 
Viruses are abundant members of the human microbiota, found throughout the body including the 185 
urinary tract. These viruses include those that infect human cells (eukaryotic viruses, Box 1) as well as 186 
both lytic and lysogenic phages. 187 
[H2] Eukaryotic viruses  188 
The urinary tract harbours a diverse eukaryotic viral community, including adenoviruses, anelloviruses, 189 
papillomaviruses, and polyomaviruses 32-36,106-116. Adenoviruses can be detected in urine 106, and can 190 
range from limited, localized infections in otherwise healthy individuals to severe and potentially fatal 191 
infections in immunocompromised individuals 107. Torque teno virus (TTV), also referred to as small 192 
anellovirus, has largely been studied in relation to immunodeficiency in renal transplant recipients 108. 193 
Rani et al. 32 collected midstream clean-catch urine from 22 kidney transplant recipients; whole-genome 194 
sequencing was conducted for the urinary viromes of these samples and 108 different subtypes of TTV 195 
were detected. The most prevalent eukaryotic viruses in urine samples are human polyomavirus 1 (BK 196 
virus) and 2 (JC virus) 109. Both of these polyomaviruses seem to have little effect on healthy individuals, 197 
but each can lead to nephropathy and hemorrhagic cystitis in immunocompromised populations 110,111. 198 
Metagenomic sequencing of the bladder microbiome (both the bacterial and viral fractions) of 30 199 
individuals enabled reconstruction of the full JC virus genome in five of the samples 33. JC virus and other 200 
polyomaviruses have also been detected in other viromes from urine samples (obtained using an 201 
undescribed voided urine collection method) 34. Human papillomaviruses (HPVs) also have been 202 
detected in voided urine 112 and bladder tissue 113,114. Certain HPV genotypes have been attributed to 203 
condylomata acuminatum of the bladder 115,116, but these high-risk genotypes associated with cervical 204 
cancer are rare. In one investigation of the urinary virome, 95% of the 20 participants sampled had HPV 205 
sequences detected in their urine 35; for eight patients, these samples were collected via intermittent 206 
catheterization and the for the others, an undescribed voided urine collection method was used. In the 207 
case of the latter, whether contamination from either the skin microbiota or the vaginal microbiota, 208 
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both of which are known to contain HPV 117, occurred is unknown. However, eukaryotic viruses are 209 
estimated to represent just a small fraction of the urinary virome 33-36. 210 
 211 
[H2] Lytic phages 212 
Lytic phages have been isolated directly from urine on numerous occasions. The first phage from urine 213 
was isolated by the co-discoverer of bacteriophages Félix d’Hérelle in 1917 when he observed that this 214 
invisible microbe lysed the Shiga bacillus, despite not knowing exactly what a phage was at the time 118. 215 
A century later, two studies isolated phages capable of infecting Pseudomonas aeruginosa from urine 216 
samples 119,120. Transmission electron microscopy (TEM) of the isolated phages provided information 217 
about the phages’ morphology, which includes a siphophage, a tailed phage with a long, thin, often 218 
flexible tail structure, 119 and two tailless phages (Fig 3) 120. A fourth Pseudomonas-infecting phage, 219 
harvested from a bacterial isolate from a urine sample collected via catheterization has been discovered 220 
(Johnson et al., in preparation). This phage is capable of lysing P. aeruginosa PAO1. Coliphages, or 221 
phages that infect E. coli, have also been isolated from voided and catheterized urine samples. Dallas 222 
and Kingsbery 121 found 100,000 colony-forming units (CFU) /ml of bacterial growth in routinely plated 223 
urine samples (collected using an unknown method) and, upon closer inspection, phage plaques. 224 
Furthermore, four coliphages were isolated from clinical urine samples and their morphologies were 225 
determined to be siphophages using TEM 119. A further seven coliphages were isolated from the bladder 226 
of four women with UUI (in urine collected via catheterization) 122. From the complete genomes of these 227 
seven coliphages, six (phages Greed, Sloth, Envy, Pride, Gluttony, and Lust) resemble coliphages that 228 
were isolated from cattle slurry 123. This observation similarity suggests that the human urinary virome 229 
might include strains found within other hosts, having a regulatory role in the urinary microbiota. The 230 
seventh coliphage identified, phage Wrath, most closely resembles a lysogenic Bacillus phage sequence. 231 
TEM images suggested that these phages had siphophage morphology (Fig 4). Testing of the host range 232 
of the phage Greed showed that in addition to its ability to lyse the laboratory strains E. coli C and K-12, 233 
it is also capable of infecting and lysing some E. coli strains isolated from urine samples, including the 234 
uropathogen E. coli CFT073 124. Thus, within the urinary microbiota, Greed might be effective in 235 
thwarting the proliferation of uropathogenic E. coli strains. However, the lytic phage population is only 236 
one part of the phage community within the lower urinary tract. 237 
 238 
[H2] Lysogenic phages  239 
Lysogenic phage communities have been routinely under-reported in the human body, a direct result of 240 
the methods used to collect and sequence viral isolates 125. In fact, evidence suggests that lysogenic 241 
phages are the most abundant phage type within the gut microbial community 126. Similar observations 242 
have been made within the bladder. Several prophages have been identified within E. coli isolates 243 
collected from catheterized urine from the bladder 127. Numerous prophage sequences have been 244 
identified within the genomes of four Gardnerella strains isolated from urine specimens obtained via 245 
catheterization from the bladders of adult women with UUI, although a lytic Gardnerella-infecting phage 246 
has yet to be isolated, possibly owing to the challenges of growing this phage in the laboratory, and is a 247 
currently unexplored area of phage biology 128. Analysis of these four genomes and other publicly 248 
available Gardnerella genomes revealed that phage infections were pervasive within the urinary 249 
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microbiota 128. This examination of lysogenic phages was then expanded to include 181 bacterial 250 
isolates, which was representative of the phylogenetic diversity within the bladder 129. These samples 251 
were collected from women with or without lower urinary tract symptoms. Over 400 phage sequences 252 
were identified; the majority (86%) of these bacterial isolates harboured one or more lysogenic phages 253 
129. Furthermore, many (57%) of the phages identified in this study 129 exhibited no sequence similarity 254 
to any known phages, indicative of a vast unexplored phage population residing in the bladder. 255 
To date, three published studies have employed a metagenomic approach to sequence the viral fraction 256 
of the urinary microbiota. The first study, conducted by Santiago-Rodriguez et al. 35, sought to determine 257 
whether the urinary virome was affected by urinary tract health status. The viral fraction (eukaryotic 258 
viruses and extracellular phages) of urine collected from 10 individuals with and 10 individuals without a 259 
diagnosed UTI were sequenced. For each cohort, samples were collected either via catheterization or 260 
voided urine from five men and five women. As previous research has shown, clean-catch studies of 261 
voided urine from women routinely contain bacterial taxa from vaginal contamination 41. Furthermore, 262 
the bacterial taxa of the male and female urinary microbiota are not identical 130,131. Only 27% of the 263 
viral sequences produced in this study were homologous to known viruses, the majority (>99%) of which 264 
represented phage genes 35, again suggesting a large unexplored phage community within the urinary 265 
tract. In a second study, urine samples were collected via the voided mid-stream clean-catch method 266 
from 14 men and eight women who received a kidney transplant 32 and the viral fraction was isolated 267 
and sequenced. Phages are present in these viromes, but this study did not mention phages and 268 
sequence data is not publicly available; instead, the authors focused solely on eukaryotic viruses. The 269 
subsequent study of Thannesberger et al. 34 also found a large phage community, but the authors 270 
concluded that the phage community primarily consisted of relatives of known species, the majority 271 
resembling Chlamydia microviruses, which infect Chlamydia spp. This study included two healthy 272 
individuals and four individuals with human cytomegalovirus (CMV) infections. However, information 273 
about how the urine was collected or demographics of the patients was not provided. This omission, 274 
compounded by the small sample size, limits our ability to frame the study’s results with respect to 275 
other virome studies. 276 
Viral diversity within the urinary tract also has been studied by sequencing the entire urinary microbiota. 277 
In 2018, Moustafa et al. 36 published a study in which metagenomic sequencing was performed for urine 278 
samples from 49 individuals with suspected UTIs (collected via the clean-catch method). As this study 279 
did not select for the viral fraction, most of the sequenced data corresponded to bacterial genetic 280 
material. Nevertheless, viral — primarily phage — sequences were detected 36. Similar to the study 281 
conducted by Santiago-Rodriguez and colleagues 35, this study examined samples from individuals with 282 
UTIs and detected sequences homologous to those from phages that infect bacteria commonly found 283 
within the urinary tract and associated with UTIs, including those of the genera Escherichia, 284 
Enterococcus, Lactobacillus and Pseudomonas 36. Abundant bacterial species harbouring prophages 285 
would result in an abundance of phages; thus, one would expect to identify phages infectious of UTI-286 
associated bacterial taxa. In a similar approach, sequencing was undertaken of urine collected using 287 
catheterization from 10 asymptomatic women and 20 women with overactive bladder 33. Partial and 288 
complete viral genomes were reconstructed in 12 of the 30 samples sequenced, including the complete 289 
genomes of novel phage strains 33. Partial and complete phage genomes also exhibited sequence 290 
homology to previously characterized lytic or lysogenic phages that infect Gardnerella, Lactobacillus and 291 
Streptococcus species. These bacterial species are dominant members of the urinary microbiota of 292 
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healthy women as well as women with overactive bladder symptoms 44; thus, one would expect to 293 
readily identify phage infection of these taxa. In sequencing both the bacterial and viral members of the 294 
microbiota, associations between phages and their hosts can be inferred. As both of these studies have 295 
highlighted, phages that infect dominant bacterial taxa within the urinary microbiota can be identified 296 
33,36. One can, therefore, postulate that novel phage sequences (phages that do not share sequence 297 
homology with any known, sequenced phage or prophage sequence) are infectious of a bacterial taxa 298 
within that same individual’s urinary microbiota, whereas more prolific phage species, which are 299 
representative of more deeply sequenced viral sequences, are probably infectious of dominant bacterial 300 
taxa. 301 
 302 
Culture-based and culture-independent studies have revealed a large, active phage population within 303 
the lower urinary tract. The diversity present has yet to be comprehensively catalogued, but the 304 
consistent finding that the majority of phage sequences detected do not resemble known, sequenced 305 
phages suggests a novel community within the urinary tract. In parallel to continued efforts to catalogue 306 
this community, future studies should conduct comparisons of the urinary virome to the viromes of 307 
other areas of the human body. In particular, comparisons to the gut virome are warranted given 308 
emerging evidence that viruses of the gut have been found elsewhere in the body 12. 309 
 310 
[H1] Challenges of studying bladder phages 311 
The bladder has orders of magnitude less microbial biomass than the gastrointestinal tract, oral cavity or 312 
vagina 43,132,133. DNA concentrations are often low, a challenge faced by both those studying the bacterial 313 
and those investigating the viral constituents of the bladder 134. Thus, two of the metagenomic studies of 314 
the urinary virome employed amplification before sequencing 34,35. This technique is efficient for 315 
increasing viral genomic material, but these amplification methods have well documented biases 17-19. 316 
For instance, multiple displacement amplification (MDA) can increase the DNA template concentration 317 
for sequencing, but small circular viral genomes are over-amplified. Both MDA and single-primer 318 
amplification (SISPA) methods have also been found to under-amplify viral genomes with GC contents at 319 
the extremes 135. Perhaps of greater concern are the methods by which urine is collected and the 320 
anatomical microbiota that the collected urine represents. The method of urine collection is a frequently 321 
debated and investigated topic in the field 55,130,134, owing to the need to balance the invasiveness of 322 
procedures during collection and the purity of the sample obtained. This debate is not unique to the 323 
bladder, urinary tract, or urine; biopsies and stool samples give quantitatively and qualitatively different 324 
results for the gut 136 and methods of sampling the gut microbiota are still being refined 137,138. Studies of 325 
voided urine have routinely observed vaginal contamination of clean-catch samples 36,48. Virome studies 326 
by Santiago-Rodriguez and colleagues 35, Rani and colleagues 32, and Moustafa and colleagues 36 327 
investigated voided urine samples. Thus, whether the viruses detected resided in the bladder and/or in 328 
the urethra, vagina, or skin remains unknown. Another study, in which the bacterial communities in the 329 
bladder were obtained via paired samples by catheterization and suprapubic aspiration from women 330 
were compared showed that both methods did not isolate microbial communities that resembled the 331 
skin or vaginal microbiomes and successfully avoided vulvovaginal contaminants 41. Moreover, the 332 
communities identified by the two methods were similar 41. Although a similar study has not been 333 
conducted comparing the virome of urines collected via catheterization and suprapubic aspiration, one 334 
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would assume that both represent the same community of the bladder microbiome. Thus, catheterized 335 
urine samples have a lower probability of contaminants than voided urine samples 127. Study of less-336 
invasive methods for collection is an ongoing pursuit 139. In a 2019 study, the use of the non-invasive 337 
Peezy midstream device (Forte Medical) was tested140. The results showed that voided urine collected 338 
by the Peezy was less prone to contamination, having a bacterial abundance distinct from the 339 
periurethra 140. This device is a promising step towards a sampling method that is less-invasive than 340 
catheterization, which is the current best method for sampling the bladder’s microbiota.  341 
 342 
[H1] Phages and urinary tract health 343 
The associations between phage communities, bacterial populations, and the human host are not yet 344 
fully understood. Some evidence suggests that phages might contribute to human health 141, in 345 
particular the gut in which they have been suggest to have roles including maintaining a stable bacterial 346 
community within the gut and providing an innate defense to pathogenic species 27,29-31,60. These studies 347 
of the gut will probably inform future studies of the urinary tract and other niches of the human body, 348 
providing a model for conducting such studies and expanding our knowledge of phage genetic diversity 349 
within the human body. Paralleling those discoveries of associations between phage communities of the 350 
gut and GI symptoms, associations have also been made within the bladder: variation was observed in 351 
the abundance of lysogenic phages in bacteria isolated from asymptomatic individuals and those with 352 
overactive bladder, in which the microbiota of women with OAB included more Lactobacillus phages 353 
than the microbiota of women without OAB 129. However, notably, the Lactobacillus species between 354 
these two cohorts varied which might be contributing to the observed difference and, therefore, 355 
warrants further investigation 129. Variation, determined via the β diversity statistic and principle 356 
component analysis, was not found in the extracellular phage populations of individuals with or without 357 
UTI symptoms 35. Although the bacterial communities differ between individuals with and without UTIs, 358 
the virome does not seem to change in response, suggesting that UTI symptoms are not associated with 359 
changes in the virome 35. Further investigation of this observation is needed as the sample size was 360 
limited. However, importantly, understanding of the diversity of phages within the urinary tract has only 361 
just begun, in contrast to the gut phage communities. Cataloguing the phage community in both 362 
asymptomatic and symptomatic individuals is a critical first step in understanding if and how phages 363 
contribute to urinary tract health. All of the aforementioned studies discovered a large collection of 364 
novel viral sequences indicative of a unique genetic diversity present within the urinary tract. Further 365 
investigation of phage–bacteria dynamics in the bladder and urinary tract could reveal indicators for 366 
early detection of symptoms. 367 
Phages could also offer a defense to the human host against pathogenic bacteria. Studies of the gut 368 
communities have revealed unexpected ways in which phages interact with human cells, organs, and 369 
immune system 12,29. The prevalence of phages on the mucosal surfaces of the gut might confer a direct 370 
benefit to the human host by protecting the epithelium from bacteria 142. This study’s findings suggest 371 
that phages and mucosal surfaces have coevolved such that phages bind to mucosal glycoproteins; this 372 
phage mucosal layer reduces adherence of bacterial pathogens 142. Changes in the mucosal phage 373 
population have been associated with ulcerative colitis 61. Evidence also suggests that phages have 374 
increased virulence to bacteria when human cells are present 143. In this study, phages were found to 375 
reduce Clostridium difficile numbers more efficiently in the presence of human cells 143. Furthermore, 376 
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phages can interact directly with human cells. Studies have found that the wild type T4 phage and its 377 
substrain HAP1 can bind to cancer cell membranes and inhibit or attenuate melanoma tumour growth 378 
144. Although phages cannot infect eukaryotic cells, there are several means in which they can enter 379 
eukaryotic cells. A phage could be a passenger, as a cell of an invasive bacterial species that harbours a 380 
phage could enter a eukaryotic cell 145,146. Alternatively, eukaryotic cells can take up free phages by 381 
endocytosis 145,147. A Staphylococcus-infecting phage was capable of infecting bovine mammary epithelial 382 
cells and clearing intracellular S. aureus 147. One study showed that phages are capable of penetrating 383 
epithelial cell layers via endocytosis with an estimated 31 billion phage particles passing through these 384 
layers of the gut into the body daily 15. Given this observation, in a study of the urinary virome, 385 
comparison with the gut virome should be considered in order to identify if urinary phages originated 386 
from the gut. Within the human body, phages can modulate immune responses 148. For instance, T4 387 
phages mediated inhibition of T-cell proliferation via the CD3 complex 149 in vitro and stimulated of 388 
humoral responses in mice in vitro and in vivo 150. Phage-mediated immunoregulation holds promise, 389 
such as for attenuating the expression of proinflammatory cytokines during UTIs 151. The mechanisms by 390 
which phages interact with the immune system remains an active area of investigation 148. 391 
Appreciation is growing of the therapeutic potential of modulating the human microbiome. Induction 392 
and release of temperate phages can lyse sensitive competitor strains or lysogenize other cells 152,153. For 393 
instance, the gut bacterium Enterococcus faecalis, which has also been associated with UTIs, uses its 394 
prophages to colonize when competing strains are present 152. Alternatively, an individual’s bacterial 395 
infection can be treated with obligately lytic phages, known as phage therapy. In the face of the 396 
increasing threat of antibiotic-resistant bacterial strains, phage therapy has regained interest 154. Phage 397 
therapy was a promising area of UTI treatment in the early 20th century. For instance, in a 1928 report, 398 
phages isolated from sewage were 90% efficient in lysing E. coli and P. aeruginosa strains isolated from 399 
catheterized urine samples 155. The USA and Western Europe abandoned phage therapy when 400 
antibiotics became commercially available (amongst other reasons) 156; this area of research and 401 
treatment continued in Eastern European countries. Phage therapy is a publicly available treatment for 402 
individuals with UTIs in Russia, Poland, and the Democratic Republic of Georgia. In one study 157, 41 E. 403 
coli and 9 Klebsiella pneumoniae strains isolated from individuals with UTI were challenged with phages 404 
from collections from the Democratic Republic of Georgia. Only one E. coli isolate was resistant to the 405 
individual phages and phage cocktails tested, and one phage was capable of lysing all K. pneumoniae 406 
strains. Similar efficiencies have been observed for other bacterial species that cause UTI symptoms. A 407 
single patient, for whom gentamicin, ceftazidime, ciprofloxacin and meropenem were unable to clear 408 
the root cause of the UTI (P. aeruginosa) for > 2 years, was successfully treated with a combination of 6 409 
phages from the Eliava Institute in Tbilisi collection 158. Phage treatment was administered via 410 
catheterization every 12 h for 10 days, and meropenem was administered starting on day 6 through 30 411 
and urine samples were negative 1 year later158. A 2-year long clinical trial of bacteriophages for treating 412 
UTI in patients undergoing transurethral resection of the prostate (NCT03140085) at the Tzulukidze 413 
National Center of Urology (Tbilisi, Georgia) concluded in 2017. Participants were treated with either an 414 
antibiotic, a phage (bacteriophage Pyo and adapted substrains of Pyo), or a placebo, the latter two were 415 
administered via catheterization for 7 days 159,160. The study was unable to draw any statistically reliable 416 
conclusions, but it did conclude that phage treatment of UTIs might be effective and safe 161. Phages 417 
have also been explored for their potential use in pretreating long-term catheters with phages to 418 
minimize bacterial biofilm development and catheter blockage, which can cause catheter-associated 419 
UTIs (CAUTIs) 162. Catheters have been pretreated with phages that infect P. aeruginosa 163, Proteus 420 
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mirabilis 164, and E. coli 165 with varied success. The pretreatment of catheters with two phages were 421 
found to considerably reduce P. mirabilis biofilms for up to 168 hours post treatment 164. 422 
Increased understanding of phage, microbiota, and human host interactions is imperative for the 423 
feasibility of phage therapy of urinary tract symptoms and infections. Phage therapy has the potential to 424 
combat antibiotic-resistant bacterial infections, and anecdotal evidence of its success certainly warrants 425 
further investigation 166. Phage therapy has already proven effective in the treatment of bacterial 426 
infections in other areas of the human body. In the highly publicized case of a life-threatening 427 
Acinetobacter baumannii infection, all modern antibiotics were found to be ineffective and over a 428 
hundred phages were tested before the few phages capable of saving the patient’s life were found 167. 429 
Phage–drug cocktails are promising as well; for instance, such a cocktail was used to clear a vascular 430 
graft P. aeruginosa infection 168. The Pseudomonas phage OMKO1, used in combination with 431 
ceftazidime, was able to completely clear the infection as bacteria resistant to the phage were more 432 
sensitive to ceftazidime and vice versa 168. All phages infect their bacterial host by binding to surface 433 
receptors, a process called adsorption (Fig. 1); these receptor binding proteins are often quite specific, 434 
leading to a narrow range of hosts (strains or species) that a particular phage can infect 73. This 435 
specificity is in direct contrast to broad-spectrum antibiotics and has the benefit of targeting the 436 
pathogen with no effect to commensal bacteria. However, this specificity means that phage 437 
therapeutics will probably have to be developed on a patient-by-patient basis. In the aforementioned A. 438 
baumannii case, nearly 100 A. baumannii phages (selected from a larger collection of phages known to 439 
infect multi-drug resistant A. baumannii strains) were screened against clinical isolates from the patient; 440 
the vast majority of the phages tested had no effect against the clinical isolates 167. A phage therapy 441 
effective for a larger patient population (n>1) will, therefore, probably be a cocktail of phages, including 442 
phages capable of infecting different strains. Phage cocktails also provide the benefit of outpacing 443 
pathogen evolution, a strategy similar to that employed for the vascular graft infection 168. 444 
 445 
Given the rise of antibiotic-resistance, phage therapy is a promising replacement or augmentation to 446 
antibiotic treatment for infections throughout the body, including infections of the urinary tract. Several 447 
clinical trials are or have been conducted, including the recent trial for UTIs 160,161, the results of which 448 
provide critical data for moving forward  449 
 450 
[H1] Conclusions 451 
Whole-genome sequencing and new enhanced culture methods have been of great benefit to the study 452 
of the microorganisms within the bladder and the rest of the lower urinary tract, but considerable work 453 
remains to be done. An ongoing debate is occurring surrounding the potential presence of vulvovaginal 454 
and/or skin bacterial contaminants in urine samples of the urinary microbiota, and the same 455 
conversation is relevant to the new study of the lower urinary tract virome. Most of the studies 456 
discussed herein, with a few exceptions 35,122,128,129, have used voided urine for isolation of lytic phages 457 
or sequencing of the urinary virome. To the best of our knowledge, the phage populations of adjacent 458 
anatomical locations have yet to be investigated so the rate of incidence of viral contamination is 459 
unknown. As we have just begun to explore the phage communities within the urinary tract, such 460 
considerations must be kept in mind. More samples of the urinary virome must be sequenced to 461 
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determine if, like in the gut 30, a core phage community exists within the bladder, the urethra, the 462 
periurethral niche and adjacent urogenital niches. Only through such efforts can we fully ascertain what 463 
a healthy and an unhealthy phage community consists of. Whether a shift from the lysogenic life cycle to 464 
the lytic cycle is a cause or consequence of bacterial community dysbiosis or urinary symptoms in 465 
currently unknown. Studies such as those by Moustafa et al. 36 and Garretto et al. 33 will be particularly 466 
powerful in capturing the dynamics between phages and their hosts, increasing understanding of their 467 
interactions. These studies should become increasingly attainable as the costs of sequencing continue to 468 
decline  469 
Knowledge of the phage communities within the lower urinary tract and their role in urinary tract health 470 
is a vital first step in the development of new strategies to treat urinary symptoms and infections. 471 
However, critical to effective and reliable phage therapy strategies is the understanding of the extant 472 
beneficial microbiota. Phage therapies should ideally cause minimal to no disturbance of this 473 
community. In contrast to broad-spectrum antibiotics, phages can be directed very narrowly toward a 474 
specific pathogen within the community. Given the observed novelty of many of the phages sequenced 475 
from urine and from the bladder 35,129, perhaps the genomes of the modifiers of urinary tract health 476 
have already been sequenced. Our understanding of the phage population of the urinary tract is in its 477 
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Table 1. Current number of viral sequences from virome studies of HMP anatomical sites.  862 
*Clusters correspond to genetically distinct groups. (Data retrieved from the Integrated Microbial 863 




  868 
Total number of metagenomic 
viral contigs 
268 29,107 48,904 2,461 422 
Unique viral clusters* 70 3,645 6,963 210 68 




Fig. 1. Lytic and lysogenic cycles of phages and their impact on microbiota. Active phages infect a 870 
susceptible bacterial host, binding to surface receptors, and inject their DNA entering into the lytic or 871 
lysogenic life cycle. In the lytic cycle (left), the phage genome replicates, producing mature virions. The 872 
phage virons then burst the host cell and diffuse through the surrounding environment. Thus, the 873 
susceptible bacteria within the microbiota are killed, leaving resistant (or non-host) bacteria. Within the 874 
lysogenic cycle (right), the phage genome either integrates into the bacterial genome (prophage) or 875 
persists as an extrachromosomal plasmid. As the infected bacterial cell reproduces, the phage genome is 876 
also replicated. Cell divisions produce a population of bacterial cells harbouring the phage genomic 877 
material. Environmental factors can induce a lysogenic (or latent phage) to enter the lytic cycle. 878 
 879 
[Reproduced by Nature Urology Reviews] 880 
 881 
 882 
Fig. 2 The process of transduction. In transduction, bacterial DNA is transferred from one cell to another 883 
by phages. Adapted with permission from Sirha et al. Nature Reviews Urology 15, 750–776 (2018) 169. 884 





Fig. 3 Phage tail morphologies. Siphoviridae families have a baseplate at the distal end of the tail to 888 
which receptor-binding proteins (RBPs), such as tail fibres and tail spikes, are attached, tailless phages 889 
are just a capsid. Adapted with permission from Nobrega et al. Nature Reviews Microbiology 16, 760–890 
773 (2018)170. 891 




Fig. 4. Bacteriophage Greed, isolated from catheterized urine microbiome sample. The phage’s capsid 896 
(head) containing the phage genomic material can be seen, as well as the phage’s tail structure. Tail 897 
fibers are not visible. The scale bar represents 50 nm. Samples were positively stained with 2% (wt/vol) 898 
uranyl acetate and observed at 80 kV using a Hitachi H-600 transmission electron microscope (TEM).  899 
 900 
